Risk Stratification for Patients with Myelodysplastic Syndrome

Adverse events associated with ponatinib in CML and ALL were shown to have decreased significantly since its approval, following various risk management measures.

A phase 3 trial of uproleselan in relapsed/refractory acute myeloid leukemia failed to meet the primary overall survival end point but showed a benefit in primary refractory patients.

Revumenib is now an FDA-approved treatment for adult and pediatric patients with relapsed/refractory KMT2A-rearranged acute leukemia.

In the phase 2 AUGMENT-101 trial, revumenib met its primary end point by achieving a complete remission or complete remission with partial blood count recovery in relapsed/refractory NPM1-mutant acute myeloid leukemia.

The FDA approved obecabtagene autoleucel for the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia.

A phase 2/3 study investigating uproleselan with standard 7+3 chemotherapy in newly diagnosed, older patients with acute myeloid leukemia did not achieve the primary end point of improved event-free survival.